H. Corominas et al., Aplasia after azathioprine administration: role of the thiopurine methyltransferase genetic polymorphism, MED CLIN, 115(8), 2000, pp. 299-301
BACKGROUND: Azathioprine is an immunosuppressor drug widely used in the tre
atment of autoimmune diseases. Adverse effects during treatment are related
to the activity of thiopurine methyltransferase (TPMT), an enzyme which pl
ays a role in azathioprine metabolism. The presence of the allelic variants
of the TPMT gene allows us to classify patients into three different group
s: high, moderate and low risk of myelosuppression after receiving standard
doses of azathioprine.
PATIENTS AND METHODS: Study of the allelic variants of the TPMT gene in the
positions 460 and 719 with PCR methods in a patient with Crohn's disease,
who developed aplasia after receiving azathioprine. The study was extended
to his relatives.
RESULTS: The patient under study carried the most frequent variant allele o
f the TPMT gene associated with low enzymatic activity. The mother and one
sister of the patient were also carriers of this allelic variant.
CONCLUSIONS: Genotyping the allelic variants of the TPMT gene is a useful m
ethod to identify patients at moderate or high risk of myelosuppression aft
er administration of azathioprine.